Jun 11 |
Sector Update: Health Care Stocks Decline Tuesday Afternoon
|
Jun 11 |
Capricor Therapeutics Announces Positive Type-B Meeting with FDA for CAP-1002 Program for Duchenne Muscular Dystrophy with an Aim to Expedite BLA Pathway
|
Jun 10 |
Capricor Advances in DMD Therapy With Positive Study Data
|
Jun 10 |
Capricor (CAPR) Advances in DMD Therapy With Positive Study Data
|
Jun 4 |
What's Going On With Capricor Therapeutics Stock Tuesday?
|
Jun 4 |
Capricor Therapeutics Announces Positive 3-Year Efficacy Results from HOPE-2 Open Label Extension Study of CAP-1002 in Duchenne Muscular Dystrophy
|
May 22 |
Capricor Therapeutics (NASDAQ:CAPR) shareholder returns have been stellar, earning 113% in 5 years
|
May 17 |
Capricor Therapeutics stock rises, Oppenheimer initiates coverage at Outperform
|
May 14 |
Capricor Therapeutics Inc (CAPR) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
|
May 14 |
Capricor Therapeutics, Inc. (CAPR) Q1 2024 Earnings Call Transcript
|